{"entity":{"id":"nct07003074","kind":"trial","name":"A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer","aka":[],"tldr":"A phase 3 trial testing TQB2102 in HR-positive / HER2-negative breast cancer and HER2-positive breast cancer, now recruiting.","summary":"A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer is a phase 3 interventional study registered as NCT07003074, led by Chia Tai Tianqing Pharmaceutical Nanjing Shunxin Pharmaceutical, and recruiting on the registry. Official title: A Randomised, Open, Multicenter, Parallel-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) Positive Recurrent or Metastatic Breast Cancer. Planned enrolment is 642 participants (estimated). The study started in 2025-06-23 and primary completion is expected in 2029-07. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT07003074","url":"https://clinicaltrials.gov/study/NCT07003074"}],"tags":["ctgov-ingest"],"related":[],"cancers":["breast-hr-positive","breast-her2-positive"],"sections":[],"technologies":[],"targets":[],"drugs":["tqb2102"],"companies":["sino-biopharm"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07003074","phase":"3","setting":"A Randomized, Open, Multicenter, Parallel-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) Positive Recurrent or Metastatic Breast Cancer","sponsor":"Chia Tai Tianqing Pharmaceutical Nanjing Shunxin Pharmaceutical","started":"2025-06-23","startedType":"actual","enrolled":642,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07003074/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"drug":[{"id":"tqb2102","kind":"drug","name":"TQB2102","route":"/drugs/tqb2102/"}],"company":[{"id":"sino-biopharm","kind":"company","name":"Sino Biopharmaceutical (Chia Tai Tianqing)","route":"/companies/sino-biopharm/"}]}}